Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol ULBP2 contributors: mct - updated : 22-04-2013
HGNC name UL16 binding protein 2
HGNC id 14894
EXPRESSION
Type
   expressed in (based on citations)
organ(s)
cell lineage
cell lines tumor cell lines
fluid/secretion
at STAGE
PROTEIN
PHYSICAL PROPERTIES globular
STRUCTURE
motifs/domains
  • glycosyl phosphatidylinositol (GPI) linkage to the membrane
  • alpha 1 and alpha 2 domain
    • conjugated GlycoP
    HOMOLOGY
    Homologene
    FAMILY
  • MHC class I family
    • CATEGORY receptor membrane
    SUBCELLULAR LOCALIZATION     plasma membrane
    text glycosylphosphatidylinositol (GPI)-anchored
    basic FUNCTION
  • enhancing NK cell-mediated target recognition
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • involvement of TP53 in the regulation of specific ULBP1, ULBP2, ULBP3 that enhance NK cell-mediated target recognition
  • IGF2BP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULBP2 and MICB
    • cell & other
    REGULATION
    activated by RAS activation that upregulates the expression of ULBP1, ULBP2, ULBP3
    Other ULBP2 cell surface expression is controlled differently by calcium, which adds to the increasing perception that cell surface expression ULBP2 is controlled by distinct signal transduction pathways
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in ovarian cancer highly correlated with that of ULBP2, and high expression of ULBP2 is an indicator of poor prognosis in ovarian cancer and may relate to T cell dysfunction in the tumor microenvironment
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker soluble ULBP2 seems to be useful to identify early-stage patients with risk of B-cell chronic lymphocytic leukemia progression
    Therapy target
    ANIMAL & CELL MODELS